ProfileGDS5678 / 1437714_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 78% 81% 81% 78% 81% 80% 79% 79% 79% 79% 78% 80% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5034879
GSM967853U87-EV human glioblastoma xenograft - Control 25.4341478
GSM967854U87-EV human glioblastoma xenograft - Control 35.7517281
GSM967855U87-EV human glioblastoma xenograft - Control 45.9594281
GSM967856U87-EV human glioblastoma xenograft - Control 55.4546778
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6335881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4906980
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.431579
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4657879
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5054479
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4307379
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4486478
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5856780
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4984479